| Dr Paul Matthew Tomaszewski, MD | |
|
6 Greenwich Office Park, Greenwich, CT 06831-5151 | |
| (203) 869-1145 | |
| (203) 618-1721 |
| Full Name | Dr Paul Matthew Tomaszewski |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 13 Years |
| Location | 6 Greenwich Office Park, Greenwich, Connecticut |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164713681 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Greenwich Hospital Association - | Greenwich, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Orthopaedic And Neurosurgery Specialists, Pllc | 5294628947 | 208 |
| Orthopaedic And Neurosurgery Specialists, Pllc | 5294628947 | 208 |
| Rehabilitation Associates Inc | 8022905322 | 297 |
News Archive
Laboratory Corporation of America Holdings announced today the immediate availability of an enhanced version of its HCV GenoSure NS3/4, a drug resistance test that screens for the Q80K polymorphism. Q80K is a naturally occurring polymorphism that develops in certain strains of HCV, making the virus less susceptible to Janssen Therapeutics' OLYSIO (simeprevir), which was recently approved by the U.S. Food and Drug Administration for the treatment of certain adult patients diagnosed with genotype 1chronic hepatitis C.
Research conducted by the Center for Autism and Related Disorders, Inc. (CARD), shines new light on the effects of a popular form of hyperbaric oxygen therapy (HBOT) treatment for children with autism and related disorders. The "Randomized Trial of Hyperbaric Oxygen Therapy for Children with Autism" study reveals that HBOT, consisting of 24% oxygen delivered at 1.3 atmospheres of pressure, does not have a significant effect on symptoms of autism.
AVANIR Pharmaceuticals, Inc. (NASDAQ:AVNR) today announced additional detailed results from the confirmatory double-blind Phase III STAR trial evaluating two doses of the investigational drug Zenvia™ (dextromethorphan/quinidine) compared to placebo in the treatment of pseudobulbar affect (PBA) among patients with underlying multiple sclerosis (MS) or amyotrophic lateral sclerosis (ALS). Over the course of the 12-week study in the MS patient subset, Zenvia 30/10 mg met the primary efficacy endpoint by reducing PBA episode rates by an incremental 11.9% beyond placebo
Penicillin, one of the scientific marvels of the 20th century, is currently losing a lot of battles it once won against bacterial infections. But scientists at the University of South Carolina have just reported a new approach to restoring its combat effectiveness, even against so-called "superbugs."
› Verified 7 days ago
| Entity Name | Orthopaedic & Neurosurgery Specialists, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033318720 PECOS PAC ID: 5294628947 Enrollment ID: O20040205000859 |
News Archive
Laboratory Corporation of America Holdings announced today the immediate availability of an enhanced version of its HCV GenoSure NS3/4, a drug resistance test that screens for the Q80K polymorphism. Q80K is a naturally occurring polymorphism that develops in certain strains of HCV, making the virus less susceptible to Janssen Therapeutics' OLYSIO (simeprevir), which was recently approved by the U.S. Food and Drug Administration for the treatment of certain adult patients diagnosed with genotype 1chronic hepatitis C.
Research conducted by the Center for Autism and Related Disorders, Inc. (CARD), shines new light on the effects of a popular form of hyperbaric oxygen therapy (HBOT) treatment for children with autism and related disorders. The "Randomized Trial of Hyperbaric Oxygen Therapy for Children with Autism" study reveals that HBOT, consisting of 24% oxygen delivered at 1.3 atmospheres of pressure, does not have a significant effect on symptoms of autism.
AVANIR Pharmaceuticals, Inc. (NASDAQ:AVNR) today announced additional detailed results from the confirmatory double-blind Phase III STAR trial evaluating two doses of the investigational drug Zenvia™ (dextromethorphan/quinidine) compared to placebo in the treatment of pseudobulbar affect (PBA) among patients with underlying multiple sclerosis (MS) or amyotrophic lateral sclerosis (ALS). Over the course of the 12-week study in the MS patient subset, Zenvia 30/10 mg met the primary efficacy endpoint by reducing PBA episode rates by an incremental 11.9% beyond placebo
Penicillin, one of the scientific marvels of the 20th century, is currently losing a lot of battles it once won against bacterial infections. But scientists at the University of South Carolina have just reported a new approach to restoring its combat effectiveness, even against so-called "superbugs."
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Paul Matthew Tomaszewski, MD 6 Greenwich Office Park, Greenwich, CT 06831-5151 Ph: (203) 869-1145 | Dr Paul Matthew Tomaszewski, MD 6 Greenwich Office Park, Greenwich, CT 06831-5151 Ph: (203) 869-1145 |
News Archive
Laboratory Corporation of America Holdings announced today the immediate availability of an enhanced version of its HCV GenoSure NS3/4, a drug resistance test that screens for the Q80K polymorphism. Q80K is a naturally occurring polymorphism that develops in certain strains of HCV, making the virus less susceptible to Janssen Therapeutics' OLYSIO (simeprevir), which was recently approved by the U.S. Food and Drug Administration for the treatment of certain adult patients diagnosed with genotype 1chronic hepatitis C.
Research conducted by the Center for Autism and Related Disorders, Inc. (CARD), shines new light on the effects of a popular form of hyperbaric oxygen therapy (HBOT) treatment for children with autism and related disorders. The "Randomized Trial of Hyperbaric Oxygen Therapy for Children with Autism" study reveals that HBOT, consisting of 24% oxygen delivered at 1.3 atmospheres of pressure, does not have a significant effect on symptoms of autism.
AVANIR Pharmaceuticals, Inc. (NASDAQ:AVNR) today announced additional detailed results from the confirmatory double-blind Phase III STAR trial evaluating two doses of the investigational drug Zenvia™ (dextromethorphan/quinidine) compared to placebo in the treatment of pseudobulbar affect (PBA) among patients with underlying multiple sclerosis (MS) or amyotrophic lateral sclerosis (ALS). Over the course of the 12-week study in the MS patient subset, Zenvia 30/10 mg met the primary efficacy endpoint by reducing PBA episode rates by an incremental 11.9% beyond placebo
Penicillin, one of the scientific marvels of the 20th century, is currently losing a lot of battles it once won against bacterial infections. But scientists at the University of South Carolina have just reported a new approach to restoring its combat effectiveness, even against so-called "superbugs."
› Verified 7 days ago
Dr. Mark Anthony Vitale, MD, MPH Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 6 Greenwich Office Park, Greenwich, CT 06831 Phone: 203-869-1145 Fax: 203-618-1721 | |
Dr. Jonathan L Berliner, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 6 Greenwich Office Park, Greenwich, CT 06831 Phone: 203-869-1145 Fax: 203-618-1721 | |
Brian F Kavanagh, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 6 Greenwich Office Park, Greenwich, CT 06831 Phone: 203-869-1145 Fax: 203-618-1721 | |
Steven E Hindman, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 6 Greenwich Office Park, Greenwich, CT 06831 Phone: 203-869-1145 Fax: 203-618-1721 | |
Francis Ennis, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 6 Greenwich Office Park, Greenwich, CT 06831 Phone: 203-869-1145 Fax: 203-618-1721 | |
Matthew Cantlon, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 6 Greenwich Office Park, Greenwich, CT 06831 Phone: 203-869-1145 Fax: 203-618-1721 |